Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00227110 · ClinicalTrials.gov registry record · Phase 4

Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 4
Development phase
55
Enrollment target

NCT00227110: Completed Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.

NCT00227110 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 55 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00227110, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 4
Development phase
55 participants
Enrollment target

Study Summary

To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2002-10
Est. Completion 2006-01
Phase Phase 4

What the finished NCT00227110 record still lists

NCT00227110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00227110 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00227110 about?

NCT00227110 is a clinical study titled "Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)". To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).

What is the current status of trial NCT00227110?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2002-10. Estimated completion is 2006-01.

What interventions are being tested in trial NCT00227110?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT00227110?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00227110's enrollment target sits among peer trials

55 1218th of 2000 higher than 778 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00227110, the US trial registry maintained by the National Library of Medicine. NCT00227110 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.